Duke Human Pharmacology and Physiology Lab (HPPL), Center for Perioperative Organ Protection (CPOP), Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina.
Department of Surgery, University of Texas Medical Branch, 301 University, Galveston, Texas.
Curr Opin Crit Care. 2020 Oct;26(5):508-515. doi: 10.1097/MCC.0000000000000757.
ICU survivors frequently suffer significant, prolonged physical disability. 'ICU Survivorship', or addressing quality-of-life impairments post-ICU care, is a defining challenge, and existing standards of care fail to successfully address these disabilities. We suggest addressing persistent catabolism by treatment with testosterone analogues combined with structured exercise is a promising novel intervention to improve 'ICU Survivorship'.
One explanation for lack of success in addressing post-ICU physical disability is most ICU patients exhibit severe testosterone deficiencies early in ICU that drives persistent catabolism despite rehabilitation efforts. Oxandrolone is an FDA-approved testosterone analogue for treating muscle weakness in ICU patients. A growing number of trials with this agent combined with structured exercise show clinical benefit, including improved physical function and safety in burns and other catabolic states. However, no trials of oxandrolone/testosterone and exercise in nonburn ICU populations have been conducted.
Critical illness leads to a catabolic state, including severe testosterone deficiency that persists throughout hospital stay, and results in persistent muscle weakness and physical dysfunction. The combination of an anabolic agent with adequate nutrition and structured exercise is likely essential to optimize muscle mass/strength and physical function in ICU survivors. Further research in ICU populations is needed.
重症监护病房(ICU)幸存者常遭受严重且持久的身体残疾。“ICU 后生存”,或解决 ICU 护理后生活质量受损问题,是一个具有挑战性的问题,现有的护理标准未能成功解决这些残疾问题。我们建议通过使用睾丸激素类似物联合结构化运动来治疗持续性分解代谢,这是改善“ICU 后生存”的一种很有前途的新干预措施。
导致 ICU 后身体残疾治疗效果不佳的一个解释是,大多数 ICU 患者在 ICU 早期就表现出严重的睾丸激素缺乏,尽管进行了康复治疗,但仍会导致持续性分解代谢。氧雄龙是一种 FDA 批准的用于治疗 ICU 患者肌肉无力的睾丸激素类似物。越来越多的关于该药物与结构化运动联合应用的临床试验显示出临床获益,包括改善烧伤和其他分解代谢状态下的身体功能和安全性。然而,在非烧伤 ICU 人群中,尚未开展关于氧雄龙/睾丸激素和运动的临床试验。
危重病会导致分解代谢状态,包括严重的睾丸激素缺乏,这种缺乏会持续整个住院期间,并导致持续性肌肉无力和身体功能障碍。合成代谢药物联合适当的营养和结构化运动可能是优化 ICU 幸存者肌肉质量/力量和身体功能的关键。需要在 ICU 人群中开展进一步的研究。